Sesamin: A Naturally Occurring Lignan Inhibits CYP3A4 by Antagonizing the Pregnane X Receptor Activation

Figure 10

Sesamin-related changes in gene expression of the phase II enzyme gene (UGT1A1) and the Nrf2 target gene (NQO1). HepG2 cells were treated with sesamin and rifampin, independently or in combination for 48 h; mRNA was collected, and the expression of (a) UGT1A1 and (b) NQO1 were analyzed by RT-PCR and normalized to the corresponding β-actin expression. The expression in DMSO-treated controls was set at 1. The results are expressed as mean ± SD (𝑛=3). *𝑃<0.05; **𝑃<0.01; and ***𝑃<0.001, as compared to DMSO-treated or 20-μM rifampin-treated cells, as indicated in the figure.

(a)

(b)